drugset / Trial / NCT01843491

A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents

NCT01843491 ↗

NaSingle-groupOpen-labelHealth-services research

Summary

This is an open label Phase 1 study of the Ad-PfCA vaccine designed to 1) provide reagents for the development and refinement of cell-mediated immunoassays for measuring the human immune response to candidate malaria vaccines (especially protective malaria vaccines such as DNA/Ad-PfCA where better assays are needed to identify the correlates of protective immunity) and 2) to provide a repository of antigen-specific PBMCs that can be used as positive and negative controls in cell mediated immunoassays.

Timeline

Start
2013-06
Primary completion
2014-06
Completion
2014-06

Outcome

Outcome not reported

Stopped: “Did not go forward with study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad-PfCA Vaccine 2e+10 unknown Intramuscular

Indications